Literature DB >> 31057099

Biased Agonism as an Emerging Strategy in the Search for Better Opioid Analgesics.

Justyna Piekielna-Ciesielska1, Karol Wtorek1, Anna Janecka1.   

Abstract

Morphine and related drugs that act through activating opioid receptors are the most effective analgesics for the relief of severe pain. They have been used for decades, despite the range of unwanted side effects that they produce, as no alternative has been found so far. The major goal of opioid research is to understand the mechanism of action of opioid receptor agonists and to improve the therapeutic utility of opioid drugs. In the search for safer and more potent analgesics, analogs with mixed opioid receptor profile gained a lot of interest. However, recently the concept of biased agonism, that highlights the fact that some ligands are able to differentially activate receptor downstream pathways, became a new approach in the design of novel drug candidates for clinical application. In this review, we summarize current knowledge on the development of opioid ligands of peptide and nonpeptide structure, showing how much opioid pharmacology evolved in recent years. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Opioid receptors; antinociceptive activity; bias factor; biased agonism; morphine; opioid peptides.

Mesh:

Substances:

Year:  2020        PMID: 31057099     DOI: 10.2174/0929867326666190506103124

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

Review 2.  Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review From Animal and Human Studies.

Authors:  Silvia Franchi; Giorgia Moschetti; Giada Amodeo; Paola Sacerdote
Journal:  Front Immunol       Date:  2019-12-12       Impact factor: 7.561

3.  Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.

Authors:  Justyna Piekielna-Ciesielska; Roberto Artali; Ammar A H Azzam; David G Lambert; Alicja Kluczyk; Luca Gentilucci; Anna Janecka
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

4.  Identification and characterization of an atypical Gαs-biased β2AR agonist that fails to evoke airway smooth muscle cell tachyphylaxis.

Authors:  Donghwa Kim; Alina Tokmakova; Lauren K Lujan; Hannah R Strzelinski; Nicholas Kim; Maliheh Najari Beidokhti; Marc A Giulianotti; Amirhossein Mafi; Jung-A A Woo; Steven S An; William A Goddard; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-07       Impact factor: 11.205

Review 5.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05

Review 6.  Insights From Molecular Dynamics Simulations of a Number of G-Protein Coupled Receptor Targets for the Treatment of Pain and Opioid Use Disorders.

Authors:  João Marcelo Lamim Ribeiro; Marta Filizola
Journal:  Front Mol Neurosci       Date:  2019-08-23       Impact factor: 5.639

Review 7.  Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs.

Authors:  Samo Lešnik; Éva Bertalan; Urban Bren; Ana-Nicoleta Bondar
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.